Erectile dysfunction (ED) is the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It is common in midlife and older adults and should be treated as a sentinel marker of underlying vascular and metabolic disease rather than an isolated sexual complaint. The clinical importance of ED stems from strong epidemiologic associations with atherosclerotic cardiovascular disease (ASCVD) and endothelial dysfunction. ED often precedes overt coronary artery disease, myocardial infarction, or stroke by several years, reflecting shared pathophysiologic pathways: impaired nitric oxide (NO) bioavailability, endothelial injury, reduced smooth muscle relaxation, and increased oxidative stress.
Mechanistically, erectile capability depends on coordinated parasympathetic input, intact vascular endothelium, and functional cavernosal smooth muscle. Sexual stimulation triggers neuronal and endothelial NO synthesis, activating guanylate cyclase to increase cyclic guanosine monophosphate (cGMP). cGMP promotes smooth muscle relaxation and increases arterial inflow while veno-occlusion traps blood within the corpora cavernosa. In ED, these steps are disrupted. Hypertension, dyslipidemia, diabetes, smoking, and obesity contribute by accelerating atherosclerosis, impairing endothelial-dependent vasodilation, and promoting inflammatory remodeling. Smoking increases sympathetic tone, reduces NO availability, and damages microvascular circulation. Elevated low-density lipoprotein and low high-density lipoprotein contribute to plaque formation and chronic vascular narrowing. High blood pressure increases shear stress and endothelial dysfunction, reducing the vessel’s capacity to dilate during arousal.
Medication safety is central when ED coexists with cardiovascular risk. Phosphodiesterase type 5 inhibitors (PDE5 inhibitors)—such as sildenafil, tadalafil, and vardenafil—enhance the NO–cGMP pathway by preventing cGMP breakdown in erectile tissue. However, the systemic vasodilatory effect can interact with nitrates. In patients using nitrates for angina or other indications, PDE5 inhibitors can produce profound hypotension because both therapies increase the cGMP axis. Therefore, coadministration is contraindicated. ED medications also require caution with potent alpha-blockers and certain antiarrhythmics depending on hemodynamic status and drug metabolism.
The clinical approach begins with risk assessment and reversible cause identification. A thorough history should address onset pattern, nocturnal/morning erections, medication and substance use (including nicotine), and psychosocial factors such as performance anxiety, depression, relationship stress, and sleep disorders. Physical examination may evaluate vascular status, secondary sexual characteristics, testicular function, and neuropathy signs. Laboratory evaluation commonly includes fasting glucose or hemoglobin A1c for diabetes, lipid profile for dyslipidemia, and morning total testosterone when hypogonadism is suspected. Because ED can be a manifestation of diffuse vascular disease, clinicians should also assess for silent CAD and quantify overall ASCVD risk.
Lifestyle modification is foundational and often improves both ED and cardiovascular outcomes. Smoking cessation reduces endothelial injury and improves vascular function over time. Weight loss decreases insulin resistance and inflammatory burden. Regular aerobic and resistance exercise improves endothelial function, lowers blood pressure, and enhances sexual function. Optimizing diet quality—emphasizing fiber-rich foods, unsaturated fats, and reduced processed carbohydrates—can improve lipid parameters. These changes can improve erectile physiology even when pharmacologic therapy is needed.
Regarding “dodgy” or non-prescription ED medications, public health guidance emphasizes that adulterated products pose significant risk. Counterfeit agents or supplements may contain undeclared PDE5 inhibitors, heavy metals, or drug analogues with unpredictable potency and contaminant profiles. Such products increase the likelihood of adverse cardiovascular events, dangerous drug–drug interactions, and treatment delays that allow progressive vascular disease. Patients should use only regulated medications prescribed by clinicians and confirm dosing and ingredients.
When PDE5 inhibitors are ineffective or not tolerated, alternative evidence-based options include vacuum erection devices, intracavernosal injections (e.g., alprostadil or combination regimens), and intraurethral therapy in selected cases. For persistent symptoms with confirmed hypogonadism, testosterone replacement may be considered after careful evaluation, balancing potential risks and ensuring appropriate monitoring.
ED is also influenced by mental health. Depression and anxiety can worsen libido and arousal pathways, increase sympathetic activation, and impair cognitive attention to erection maintenance. Addressing psychological contributors through counseling or sex therapy, and treating underlying depression or anxiety disorders, can improve outcomes. Importantly, the vascular disease component should not be assumed away; in high-risk patients, ED warrants concurrent cardiovascular evaluation.
In summary, erectile dysfunction is a multifactorial condition tightly linked to endothelial dysfunction and atherosclerotic risk. In patients with hypertension, dyslipidemia, smoking history, and metabolic risk factors, ED should trigger structured medical assessment, evidence-based pharmacotherapy with attention to contraindications (notably nitrates), and aggressive lifestyle interventions. Avoiding unregulated ED medications is essential for safety. Source: dninnio (@dninio)
Daniel Ninio: @goodfoodgal He was also a fat smoker with high blood pressure, terrible cholesterol taking dodgy ED medications on a fluid only fast. #breaking
— @dninio May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
